Engineered immune cells take aim at stubborn leukemia
NCT ID NCT05995041
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CLL-1, CD33, CD38, and CD123). The study aims to see if this treatment is safe and whether it can shrink tumors or lead to remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
universal CAR T cells targeting CLL-1, CD33, CD38, and CD123
What this could lead to
If successful, this approach could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia, potentially improving remission rates.
What could go wrong
This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. CAR T cell therapy can cause severe side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••